ID   HPPE_STRWE              Reviewed;         198 AA.
AC   Q56185;
DT   03-APR-2013, integrated into UniProtKB/Swiss-Prot.
DT   01-NOV-1996, sequence version 1.
DT   24-JUN-2015, entry version 71.
DE   RecName: Full=(S)-2-hydroxypropylphosphonic acid epoxidase;
DE            EC=1.11.1.23;
DE   AltName: Full=Fosfomycin biosynthesis protein 4;
DE   AltName: Full=Hydroxypropylphosphonate epoxidase;
DE            Short=Sw-hppE;
GN   Name=hppE; Synonyms=fom4;
OS   Streptomyces wedmorensis.
OC   Bacteria; Actinobacteria; Streptomycetales; Streptomycetaceae;
OC   Streptomyces.
OX   NCBI_TaxID=43759;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=7500951; DOI=10.1007/BF00290527;
RA   Hidaka T., Goda M., Kuzuyama T., Takei N., Hidaka M., Seto H.;
RT   "Cloning and nucleotide sequence of fosfomycin biosynthetic genes of
RT   Streptomyces wedmorensis.";
RL   Mol. Gen. Genet. 249:274-280(1995).
RN   [2]
RP   PHOSPHINOTHRICIN TRIPEPTIDE AND FOSFOMYCIN BIOSYNTHESIS.
RX   PubMed=19516340; DOI=10.1038/nature07972;
RA   Cicchillo R.M., Zhang H., Blodgett J.A., Whitteck J.T., Li G.,
RA   Nair S.K., van der Donk W.A., Metcalf W.W.;
RT   "An unusual carbon-carbon bond cleavage reaction during
RT   phosphinothricin biosynthesis.";
RL   Nature 459:871-874(2009).
RN   [3]
RP   X-RAY CRYSTALLOGRAPHY (1.80 ANGSTROMS) IN COMPLEX WITH COBALT AND
RP   (S)-2-HYDROXYPROPYLPHOSPHONATE, FUNCTION, CATALYTIC ACTIVITY,
RP   COFACTOR, SUBUNIT, PATHWAY, AND MUTAGENESIS OF LYS-23; TYR-105 AND
RP   GLU-142.
RX   PubMed=16015285; DOI=10.1038/nature03924;
RA   Higgins L.J., Yan F., Liu P., Liu H.W., Drennan C.L.;
RT   "Structural insight into antibiotic fosfomycin biosynthesis by a
RT   mononuclear iron enzyme.";
RL   Nature 437:838-844(2005).
RN   [4]
RP   X-RAY CRYSTALLOGRAPHY (1.70 ANGSTROMS) IN COMPLEX WITH ZINC, AND
RP   FUNCTION.
RX   PubMed=16186494; DOI=10.1073/pnas.0504314102;
RA   McLuskey K., Cameron S., Hammerschmidt F., Hunter W.N.;
RT   "Structure and reactivity of hydroxypropylphosphonic acid epoxidase in
RT   fosfomycin biosynthesis by a cation- and flavin-dependent mechanism.";
RL   Proc. Natl. Acad. Sci. U.S.A. 102:14221-14226(2005).
RN   [5]
RP   X-RAY CRYSTALLOGRAPHY (2.10 ANGSTROMS) IN COMPLEX WITH IRON.
RX   PubMed=21682308; DOI=10.1021/ja2025728;
RA   Yun D., Dey M., Higgins L.J., Yan F., Liu H.W., Drennan C.L.;
RT   "Structural basis of regiospecificity of a mononuclear iron enzyme in
RT   antibiotic fosfomycin biosynthesis.";
RL   J. Am. Chem. Soc. 133:11262-11269(2011).
CC   -!- FUNCTION: Non-heme-dependent dioxygenase that catalyzes the
CC       oxidative epoxidation of (S)-2-hydroxypropylphosphonate into
CC       (1R,2S)-epoxypropylphosphonate, the final step in the biosynthesis
CC       of fosfomycin antibiotic. {ECO:0000269|PubMed:16015285,
CC       ECO:0000269|PubMed:16186494}.
CC   -!- CATALYTIC ACTIVITY: (S)-2-hydroxypropylphosphonate + H(2)O(2) =
CC       (1R,2S)-1,2-epoxypropylphosphonate + 2 H(2)O.
CC       {ECO:0000269|PubMed:16015285}.
CC   -!- COFACTOR:
CC       Name=Fe(2+); Xref=ChEBI:CHEBI:29033;
CC         Evidence={ECO:0000269|PubMed:16015285};
CC       Note=Binds 1 Fe(2+) ion per subunit.
CC       {ECO:0000269|PubMed:16015285};
CC   -!- PATHWAY: Antibiotic biosynthesis; phosphinothricin biosynthesis.
CC       {ECO:0000269|PubMed:16015285}.
CC   -!- SUBUNIT: Homotetramer. {ECO:0000269|PubMed:16015285,
CC       ECO:0000269|PubMed:16186494, ECO:0000269|PubMed:21682308}.
CC   -!- MISCELLANEOUS: Phosphinothricin tripeptide (PTT) herbicide and
CC       fosfomycin antibiotic biosynthesiz pathways share early steps
CC       starting with phosphoenolpyruvate before the pathways diverge
CC       after formation of 2-hydroxyethylphosphonate (HEP). HppE is
CC       involved in fosfomycin biosynthesis after divergence of the 2
CC       pathways (PubMed:19516340). {ECO:0000305|PubMed:19516340}.
CC   -!- SIMILARITY: Belongs to the non-heme iron-dependent dioxygenase
CC       family. {ECO:0000305}.
CC   -!- SIMILARITY: Contains 1 HTH cro/C1-type DNA-binding domain.
CC       {ECO:0000255|PROSITE-ProRule:PRU00257}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AB016934; BAA32491.1; -; Genomic_DNA.
DR   PIR; S60215; S60215.
DR   RefSeq; WP_033205181.1; NZ_JNWK01000026.1.
DR   PDB; 1ZZ6; X-ray; 2.00 A; A/B=1-198.
DR   PDB; 1ZZ7; X-ray; 2.10 A; A/B=1-198.
DR   PDB; 1ZZ8; X-ray; 2.30 A; A/B/C=1-198.
DR   PDB; 1ZZ9; X-ray; 2.40 A; A/B/C=1-198.
DR   PDB; 1ZZB; X-ray; 2.30 A; A/B=1-198.
DR   PDB; 1ZZC; X-ray; 1.80 A; A/B=1-198.
DR   PDB; 2BNM; X-ray; 1.70 A; A/B=1-198.
DR   PDB; 2BNN; X-ray; 2.50 A; A/B=1-198.
DR   PDB; 2BNO; X-ray; 1.90 A; A/B=1-198.
DR   PDB; 3SCF; X-ray; 2.85 A; A/B/C=1-198.
DR   PDB; 3SCG; X-ray; 3.00 A; A/B/C=1-198.
DR   PDB; 3SCH; X-ray; 2.10 A; A/B=1-198.
DR   PDB; 4J1W; X-ray; 2.72 A; A/B/C=1-198.
DR   PDB; 4J1X; X-ray; 2.80 A; A/B/C=2-198.
DR   PDBsum; 1ZZ6; -.
DR   PDBsum; 1ZZ7; -.
DR   PDBsum; 1ZZ8; -.
DR   PDBsum; 1ZZ9; -.
DR   PDBsum; 1ZZB; -.
DR   PDBsum; 1ZZC; -.
DR   PDBsum; 2BNM; -.
DR   PDBsum; 2BNN; -.
DR   PDBsum; 2BNO; -.
DR   PDBsum; 3SCF; -.
DR   PDBsum; 3SCG; -.
DR   PDBsum; 3SCH; -.
DR   PDBsum; 4J1W; -.
DR   PDBsum; 4J1X; -.
DR   ProteinModelPortal; Q56185; -.
DR   SMR; Q56185; 5-198.
DR   BioCyc; MetaCyc:MONOMER-13661; -.
DR   BRENDA; 1.11.1.23; 6118.
DR   BRENDA; 1.14.19.7; 6118.
DR   UniPathway; UPA00168; -.
DR   EvolutionaryTrace; Q56185; -.
DR   GO; GO:0051213; F:dioxygenase activity; IEA:UniProtKB-KW.
DR   GO; GO:0008198; F:ferrous iron binding; IDA:UniProtKB.
DR   GO; GO:0016717; F:oxidoreductase activity, acting on paired donors, with oxidation of a pair of donors resulting in the reduction of molecular oxygen to two molecules of water; IDA:UniProtKB.
DR   GO; GO:0043565; F:sequence-specific DNA binding; IEA:InterPro.
DR   GO; GO:0017000; P:antibiotic biosynthetic process; IEA:UniProtKB-KW.
DR   GO; GO:0055114; P:oxidation-reduction process; IDA:UniProtKB.
DR   GO; GO:1901766; P:phosphinothricin biosynthetic process; IDA:UniProtKB.
DR   GO; GO:0051289; P:protein homotetramerization; IDA:UniProtKB.
DR   Gene3D; 1.10.260.40; -; 1.
DR   Gene3D; 2.60.120.10; -; 1.
DR   InterPro; IPR001387; Cro/C1-type_HTH.
DR   InterPro; IPR013096; Cupin_2.
DR   InterPro; IPR010982; Lambda_DNA-bd_dom.
DR   InterPro; IPR014710; RmlC-like_jellyroll.
DR   InterPro; IPR011051; RmlC_Cupin.
DR   Pfam; PF07883; Cupin_2; 1.
DR   Pfam; PF01381; HTH_3; 1.
DR   SMART; SM00530; HTH_XRE; 1.
DR   SUPFAM; SSF47413; SSF47413; 1.
DR   SUPFAM; SSF51182; SSF51182; 1.
DR   PROSITE; PS50943; HTH_CROC1; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Antibiotic biosynthesis; Dioxygenase; DNA-binding; Iron;
KW   Metal-binding; NAD; Oxidoreductase.
FT   CHAIN         1    198       (S)-2-hydroxypropylphosphonic acid
FT                                epoxidase.
FT                                /FTId=PRO_0000422030.
FT   DOMAIN       15     70       HTH cro/C1-type. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00257}.
FT   DNA_BIND     26     45       H-T-H motif. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00257}.
FT   METAL       138    138       Iron; via tele nitrogen.
FT                                {ECO:0000269|PubMed:21682308}.
FT   METAL       142    142       Iron. {ECO:0000269|PubMed:21682308}.
FT   METAL       180    180       Iron; via tele nitrogen.
FT                                {ECO:0000269|PubMed:21682308}.
FT   BINDING      23     23       Substrate.
FT   BINDING      97     97       Substrate.
FT   BINDING     105    105       Substrate.
FT   BINDING     135    135       Substrate.
FT   MUTAGEN      23     23       K->A: Abolishes (S)-2-
FT                                hydroxypropylphosphonic acid epoxidase
FT                                activity. {ECO:0000269|PubMed:16015285}.
FT   MUTAGEN     105    105       Y->F: Abolishes (S)-2-
FT                                hydroxypropylphosphonic acid epoxidase
FT                                activity. {ECO:0000269|PubMed:16015285}.
FT   MUTAGEN     142    142       E->A: Abolishes (S)-2-
FT                                hydroxypropylphosphonic acid epoxidase
FT                                activity. {ECO:0000269|PubMed:16015285}.
FT   HELIX         6     21       {ECO:0000244|PDB:2BNM}.
FT   HELIX        26     33       {ECO:0000244|PDB:2BNM}.
FT   HELIX        37     44       {ECO:0000244|PDB:2BNM}.
FT   TURN         45     47       {ECO:0000244|PDB:2BNM}.
FT   HELIX        53     62       {ECO:0000244|PDB:2BNM}.
FT   HELIX        68     70       {ECO:0000244|PDB:2BNM}.
FT   STRAND       79     81       {ECO:0000244|PDB:1ZZ8}.
FT   HELIX        87     89       {ECO:0000244|PDB:2BNM}.
FT   STRAND       95     97       {ECO:0000244|PDB:2BNO}.
FT   STRAND      103    107       {ECO:0000244|PDB:2BNM}.
FT   STRAND      118    124       {ECO:0000244|PDB:2BNM}.
FT   HELIX       129    131       {ECO:0000244|PDB:2BNM}.
FT   STRAND      139    149       {ECO:0000244|PDB:2BNM}.
FT   STRAND      151    156       {ECO:0000244|PDB:2BNM}.
FT   STRAND      162    166       {ECO:0000244|PDB:2BNM}.
FT   STRAND      171    174       {ECO:0000244|PDB:2BNM}.
FT   STRAND      180    185       {ECO:0000244|PDB:2BNM}.
FT   STRAND      191    198       {ECO:0000244|PDB:2BNM}.
SQ   SEQUENCE   198 AA;  21337 MW;  550D70A1D0D2FC56 CRC64;
     MSNTKTASTG FAELLKDRRE QVKMDHAALA SLLGETPETV AAWENGEGGE LTLTQLGRIA
     HVLGTSIGAL TPPAGNDLDD GVIIQMPDER PILKGVRDNV DYYVYNCLVR TKRAPSLVPL
     VVDVLTDNPD DAKFNSGHAG NEFLFVLEGE IHMKWGDKEN PKEALLPTGA SMFVEEHVPH
     AFTAAKGTGS AKLIAVNF
//
